NCT07802626: Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing
- State
- Not started
- Phase
- Phase 3
- People
- 1,084 planned
- Started
- 30 Oct 2026
- Primary completion
- 30 Oct 2034
- Arms
- Cohort A, Arm 2
- Results
- None posted
- 3 Sep 2026: Trial registered